Aurobindo Pharma Ltd is pleased to announce that it has received approvals from the Medicines Control Council (MCC) to manufacture and market 9 products in South Africa. These products are estimated to have a generic market size of ZAR 165 million in the local market. The products approved are as follows:
1. Product Name : Auro-Lisinopril Co Active ingredient : Lisinopril+HCTZ Dosage Form : FDC Strength: 10+12.5mg,20+12.5mg Category : CVS
2. Product Name : Auro-Amiodipine Active ingredient : Amiodipine Dosage Form : Tablet Strength: 5mg,10mg Category : CVS
3. Product Name : Auro-Finasteride Active ingredient : Finasleride Dosage Form : Tablet Strength: 5mg Category : BPH
4. Product Name : Zinoxime Active ingredient : Cefuroxime Axetil Dosage Form : Tablet Strength: 125mg, 250mg,500mg Category : Anti-infective
5. Product Name : Zolid Active ingredient : Sertraline HCL Dosage Form : Tablet Strength: 50mg,100mg Category : CNS
6. Product Name : Yomax Active ingredient : Amoxycillin Dosage Form : Capsuals Strength: 250mg, 500mg Category : Anti-infective
7. Product Name : Lazivir Active ingredient : Lamivudine / Zidovudine + Abacavir Dosage Form : FDC Strength: 150/300+300mg Category : ARV
8. Product Name : Lisinozide Active ingredient : Lisinopril+HCTZ Dosage Form : Tablet Strength: 10mg,20mg Category : CVS
9. Product Name : Profine Active ingredient : Finasteride Dosage Form : Tablet Strength: 5mg Category : BPH (FDC: Fixed Dose combination, CVS: Cardio Vascular System, BPH: Benign Prostatic Hyperplasia CNS: Central Nervous System, ARV: Anti-RetroVirals)
Aurobindo now has a total of 31 marketing authorizations approved by the MCC.
The stock closed the day at Rs.340.95, up by Rs.3.50 or 1.04%. The stock hit an intraday high of Rs.344 and low of Rs.320.
The total traded quantity was 50088 compared to 2 week average of 65489.
|
